# Phase IIIB Subcutaneous Abatacept Monotherapy Study

> **NCT00547521** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 119 (actual)

## Conditions studied

- Rheumatoid Arthritis (RA)

## Interventions

- **DRUG:** abatacept
- **DRUG:** Methotrexate (MTX)

## Key facts

- **NCT ID:** NCT00547521
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2008-12
- **Final completion:** 2014-02
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2015-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00547521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00547521, "Phase IIIB Subcutaneous Abatacept Monotherapy Study". Retrieved via MORVS 2026-10-24 from https://api.morvs.ai/clinical/NCT00547521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*